150 related articles for article (PubMed ID: 38906565)
21. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
22. Physical performance is preserved after regression of left ventricular hypertrophy.
Lacourcière Y; Poirier L; Cléroux J
J Cardiovasc Pharmacol; 1997 Sep; 30(3):383-91. PubMed ID: 9300324
[TBL] [Abstract][Full Text] [Related]
23. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension.
Takami T; Shigematsu M
Clin Exp Hypertens; 2003 Nov; 25(8):525-35. PubMed ID: 14649310
[TBL] [Abstract][Full Text] [Related]
24. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F; Malmqvist K; Ohman KP; Kahan T
J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
[TBL] [Abstract][Full Text] [Related]
25. Regression of left ventricular hypertrophy. How and why?
Devereux RB
JAMA; 1996 May; 275(19):1517-8. PubMed ID: 8622230
[No Abstract] [Full Text] [Related]
26. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
27. Prehypertension is real and can be associated with target organ damage.
Materson BJ; Garcia-Estrada M; Degraff SB; Preston RA
J Am Soc Hypertens; 2017 Nov; 11(11):704-708. PubMed ID: 28965768
[TBL] [Abstract][Full Text] [Related]
28. Treatment of arterial hypertension in the elderly using enalapril.
Terranova R; Luca S; Calanna A
Minerva Med; 1999 Sep; 90(9):333-7. PubMed ID: 10719438
[TBL] [Abstract][Full Text] [Related]
29. Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death.
Messerli FH; Soria F
Cardiovasc Drugs Ther; 1994 Aug; 8 Suppl 3():557-63. PubMed ID: 7841089
[TBL] [Abstract][Full Text] [Related]
30. Comparison of therapeutic studies on regression of left ventricular hypertrophy.
Schmieder RE; Schlaich MP
Adv Exp Med Biol; 1997; 432():191-8. PubMed ID: 9433526
[TBL] [Abstract][Full Text] [Related]
31. The heart and vascular changes in hypertension.
Leonetti G; Cuspidi C
J Hypertens Suppl; 1995 Aug; 13(2):S29-34. PubMed ID: 8576785
[TBL] [Abstract][Full Text] [Related]
32. Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?
Frohlich ED
J Am Coll Cardiol; 2004 Jun; 43(12):2216-8. PubMed ID: 15193682
[No Abstract] [Full Text] [Related]
33. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.
Cağlar N; Dincer I
Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1359-68. PubMed ID: 22288296
[TBL] [Abstract][Full Text] [Related]
34. [Controlling blood pressure by centrally acting drugs--still a topic?].
Steckelings UM; Unger T
Fortschr Med; 1994 Jan; 112(3):25-6. PubMed ID: 8144121
[No Abstract] [Full Text] [Related]
35. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
[TBL] [Abstract][Full Text] [Related]
36. [The effect of long-term uncontrolled antihypertensive therapy on the echocardiographic signs of left-heart hypertrophy in patients with mild and moderate arterial hypertension].
Lerman OV; Metelitsa VI; Filatova NP; Duda SG; Malysheva NV; Vygodin VA
Ter Arkh; 1997; 69(1):43-6. PubMed ID: 9163049
[TBL] [Abstract][Full Text] [Related]
37. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension.
Fogari R; Zoppi A; Mugellini A; Tettamanti F; Lusardi P; Corradi L
Eur Heart J; 1995 Aug; 16(8):1120-5. PubMed ID: 8665975
[TBL] [Abstract][Full Text] [Related]
38. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy.
Islim IF; Watson RD; Ihenacho HN; Ebanks M; Singh SP
Cardiology; 2001; 96 Suppl 1():10-8. PubMed ID: 11574741
[TBL] [Abstract][Full Text] [Related]
39. Hypertension treatment for older people-navigating between Scylla and Charybdis.
Conroy SP; Westendorp RGJ; Witham MD
Age Ageing; 2018 Jul; 47(4):505-508. PubMed ID: 29788097
[TBL] [Abstract][Full Text] [Related]
40. Effect of 1 year of lisinopril treatment on cardiac autonomic control in hypertensive patients with left ventricular hypertrophy.
Petretta M; Bonaduce D; Marciano F; Bianchi V; Valva G; Apicella C; de Luca N; Gisonni P
Hypertension; 1996 Mar; 27(3 Pt 1):330-8. PubMed ID: 8698434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
